diaDexus Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2011
2012
2013
2014
2015
Sales/Revenue
16,384.00
20,776.00
24,884.00
26,423.00
18,114.00
Cost of Goods Sold (COGS) incl. D&A
5,404.00
6,296.00
7,222.00
7,362.00
5,362.00
Gross Income
10,980.00
14,480.00
17,662.00
19,061.00
12,752.00
SG&A Expense
18,825.00
16,878.00
19,677.00
25,481.00
18,117.00
EBIT
7,845.00
2,398.00
2,015.00
6,420.00
5,365.00
Unusual Expense
-
-
-
743.00
115.00
Non Operating Income/Expense
19.00
10.00
340.00
87.00
51.00
Interest Expense
-
395.00
488.00
1,379.00
1,857.00
Pretax Income
7,482.00
2,787.00
2,159.00
8,452.00
7,155.00
Income Tax
1.00
2.00
5.00
15.00
11.00
Consolidated Net Income
7,483.00
2,789.00
2,164.00
8,467.00
7,166.00
Net Income
7,483.00
2,789.00
2,164.00
8,467.00
7,166.00
Net Income After Extraordinaries
7,483.00
2,789.00
2,164.00
8,467.00
7,166.00
Net Income Available to Common
7,483.00
2,789.00
2,164.00
8,467.00
7,166.00
EPS (Basic)
2.10
0.75
0.60
2.30
1.83
Basic Shares Outstanding
3,537.80
3,546.60
3,622.00
3,679.90
3,911.30
EPS (Diluted)
2.12
0.79
0.60
2.30
1.83
Diluted Shares Outstanding
3,537.80
3,546.60
3,622.00
3,679.90
3,911.30
EBITDA
7,254.00
1,895.00
1,484.00
5,911.00
5,008.00
Non-Operating Interest Income
344.00
16.00
4.00
3.00
3.00

About diaDexus

View Profile
Address
349 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.diadexus.com
Updated 07/08/2019
Diadexus, Inc. engages in the research, development, and commercialization of pharmaceutical products. It operates through the following geographical segments: United States, Europe, and Rest of the World. Its portfolio intends to treat cardiovascular diseases.